Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis
BackgroundPulmonary fibrosis is one of the sequelae of the COVID-19, which seriously affects the quality of life of survivors. Currently, there are no optimal evidence based guidelines targeting this population.Case PresentationWe report a 66-year-old female patient without underlying comorbidities...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.925703/full |
| _version_ | 1818535243909431296 |
|---|---|
| author | Xianglin Zhou Xianglin Zhou Xianglin Zhou Danhui Yang Danhui Yang Danhui Yang Xianglong Kong Chengli Wei Chengli Wei Chengli Wei Siqi LvQiu Siqi LvQiu Siqi LvQiu Lin Wang Lin Wang Lin Wang Yongkang Lin Yongkang Lin Yongkang Lin Zhilan Yin Zhiguo Zhou Hong Luo Hong Luo Hong Luo |
| author_facet | Xianglin Zhou Xianglin Zhou Xianglin Zhou Danhui Yang Danhui Yang Danhui Yang Xianglong Kong Chengli Wei Chengli Wei Chengli Wei Siqi LvQiu Siqi LvQiu Siqi LvQiu Lin Wang Lin Wang Lin Wang Yongkang Lin Yongkang Lin Yongkang Lin Zhilan Yin Zhiguo Zhou Hong Luo Hong Luo Hong Luo |
| author_sort | Xianglin Zhou |
| collection | DOAJ |
| description | BackgroundPulmonary fibrosis is one of the sequelae of the COVID-19, which seriously affects the quality of life of survivors. Currently, there are no optimal evidence based guidelines targeting this population.Case PresentationWe report a 66-year-old female patient without underlying comorbidities admitted to Changsha Public Health Center because of COVID-19. During hospitalization, she developed co-bacterial infection and acute respiratory distress syndrome, and received broad-spectrum antibacterial therapy, invasive mechanical ventilation and extracorporeal membrane oxygenation. After the acute phase, she developed post-COVID-19 pulmonary fibrosis subsequently treated with pirfenidone. Over 96 weeks after pirfenidone treatment, her modified Medical Research Council Dyspnea level improved to 2 from 4 at discharge. Her 6 minutes walk test distance, total lung capacity, and diffusion capacity for carbon monoxide all increased. Chest CT performed on 2 years after illness onset showed regressing fibrosis. The Hospital Anxiety and Depression Scale, Athens Insomnia Scale, and 36-Item Short Form Health Survey questionnaire all improved.ConclusionPost-COVID-19 pulmonary fibrosis is a challenging consequence of COVID-19, and our case suggests that pirfenidone may be an effective treatment option. |
| first_indexed | 2024-12-11T18:22:15Z |
| format | Article |
| id | doaj.art-2854cd3fdc9d44aa8f812c101a8005f1 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-11T18:22:15Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-2854cd3fdc9d44aa8f812c101a8005f12022-12-22T00:55:12ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-06-01910.3389/fmed.2022.925703925703Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary FibrosisXianglin Zhou0Xianglin Zhou1Xianglin Zhou2Danhui Yang3Danhui Yang4Danhui Yang5Xianglong Kong6Chengli Wei7Chengli Wei8Chengli Wei9Siqi LvQiu10Siqi LvQiu11Siqi LvQiu12Lin Wang13Lin Wang14Lin Wang15Yongkang Lin16Yongkang Lin17Yongkang Lin18Zhilan Yin19Zhiguo Zhou20Hong Luo21Hong Luo22Hong Luo23Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, ChinaResearch Unit of Respiratory Disease, Central South University, Changsha, ChinaHunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, ChinaDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, ChinaResearch Unit of Respiratory Disease, Central South University, Changsha, ChinaHunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, ChinaRespiratory Medicine, The First Hospital of Changsha, Changsha, ChinaDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, ChinaResearch Unit of Respiratory Disease, Central South University, Changsha, ChinaHunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, ChinaDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, ChinaResearch Unit of Respiratory Disease, Central South University, Changsha, ChinaHunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, ChinaDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, ChinaResearch Unit of Respiratory Disease, Central South University, Changsha, ChinaHunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, ChinaDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, ChinaResearch Unit of Respiratory Disease, Central South University, Changsha, ChinaHunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, ChinaDepartment of Radiology, The Second Xiangya Hospital, Central South University, Changsha, ChinaRespiratory Medicine, The First Hospital of Changsha, Changsha, ChinaDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, ChinaResearch Unit of Respiratory Disease, Central South University, Changsha, ChinaHunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, ChinaBackgroundPulmonary fibrosis is one of the sequelae of the COVID-19, which seriously affects the quality of life of survivors. Currently, there are no optimal evidence based guidelines targeting this population.Case PresentationWe report a 66-year-old female patient without underlying comorbidities admitted to Changsha Public Health Center because of COVID-19. During hospitalization, she developed co-bacterial infection and acute respiratory distress syndrome, and received broad-spectrum antibacterial therapy, invasive mechanical ventilation and extracorporeal membrane oxygenation. After the acute phase, she developed post-COVID-19 pulmonary fibrosis subsequently treated with pirfenidone. Over 96 weeks after pirfenidone treatment, her modified Medical Research Council Dyspnea level improved to 2 from 4 at discharge. Her 6 minutes walk test distance, total lung capacity, and diffusion capacity for carbon monoxide all increased. Chest CT performed on 2 years after illness onset showed regressing fibrosis. The Hospital Anxiety and Depression Scale, Athens Insomnia Scale, and 36-Item Short Form Health Survey questionnaire all improved.ConclusionPost-COVID-19 pulmonary fibrosis is a challenging consequence of COVID-19, and our case suggests that pirfenidone may be an effective treatment option.https://www.frontiersin.org/articles/10.3389/fmed.2022.925703/fullpulmonary fibrosispost-COVID-19pirfenidonelong COVIDsequelae |
| spellingShingle | Xianglin Zhou Xianglin Zhou Xianglin Zhou Danhui Yang Danhui Yang Danhui Yang Xianglong Kong Chengli Wei Chengli Wei Chengli Wei Siqi LvQiu Siqi LvQiu Siqi LvQiu Lin Wang Lin Wang Lin Wang Yongkang Lin Yongkang Lin Yongkang Lin Zhilan Yin Zhiguo Zhou Hong Luo Hong Luo Hong Luo Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis Frontiers in Medicine pulmonary fibrosis post-COVID-19 pirfenidone long COVID sequelae |
| title | Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis |
| title_full | Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis |
| title_fullStr | Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis |
| title_full_unstemmed | Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis |
| title_short | Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis |
| title_sort | case report pirfenidone in the treatment of post covid 19 pulmonary fibrosis |
| topic | pulmonary fibrosis post-COVID-19 pirfenidone long COVID sequelae |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.925703/full |
| work_keys_str_mv | AT xianglinzhou casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT xianglinzhou casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT xianglinzhou casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT danhuiyang casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT danhuiyang casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT danhuiyang casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT xianglongkong casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT chengliwei casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT chengliwei casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT chengliwei casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT siqilvqiu casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT siqilvqiu casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT siqilvqiu casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT linwang casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT linwang casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT linwang casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT yongkanglin casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT yongkanglin casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT yongkanglin casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT zhilanyin casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT zhiguozhou casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT hongluo casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT hongluo casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis AT hongluo casereportpirfenidoneinthetreatmentofpostcovid19pulmonaryfibrosis |